Navigation Links
Roche and Pharmasset To Present the R7128 Monotherapy Resistance Profile
Date:2/6/2008

-- Study concludes there was no evidence of the development of viral resistance to R7128 after 2 weeks of monotherapy in hepatitis C patients --

PRINCETON, N.J., Feb. 6 /PRNewswire-FirstCall/ -- Pharmasset (Nasdaq: VRUS) and Roche will present the R7128 monotherapy resistance profile at the EASL-AASLD-APASL-ALEH-IASL Conference on Hepatitis B & C Virus Resistance to Antiviral Therapies being held in Paris, France from February 14-16, 2008. The scientific abstract for poster board no. 36, entitled "Lack of Viral Resistance after 14-day Monotherapy Treatment with R7128 in Treatment-experienced Patients Infected with HCV Genotype 1," is currently available on the conference website at http://www.easl.ch/hepatitis-conference/program/session1.asp. The poster presentation will be available for download in PDF format after it is presented on February 14, 2008 in the "Events & Presentations" section of Pharmasset's website at http://investor.pharmasset.com/events.cfm.

About R7128

R7128 is being developed for the treatment of chronic HCV infection through Pharmasset's collaboration with Roche. R7128 is a prodrug of PSI-6130, a nucleoside analog inhibitor of HCV RNA polymerase. A prodrug is a chemically modified form of a molecule designed to enhance the absorption, distribution and metabolic properties of that molecule.

In a Phase 1 clinical trial, R7128 demonstrated potent, dose-dependent antiviral activity across four patient cohorts (n=40) receiving 750mg or 1500mg administered either once-daily or twice-daily for 2 weeks as monotherapy. The greatest mean decrease in HCV RNA from baseline was observed in the patient cohort that received 1500mg twice-daily, the highest dose of R7128 administered in the study. These patients experienced a mean 2.7 log10 IU/mL (>99%) decrease in HCV R
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Roche responds to announcement of IDEAL hepatitis C trial results
2. Roche Submits Application for FDA Approval of ACTEMRA(R) for the Treatment of Rheumatoid Arthritis
3. Two Pivotal Phase III Studies for Roches ACTEMRA(TM) (tocilizumab) Demonstrate Significant Improvement in Rheumatoid Arthritis Symptoms
4. Roches Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks
5. Roche Diagnostics HIV Viral Load Test Used in Clinical Trials for Isentress, a New Class of HIV Drug
6. Roche Announces Positive Results in Solid Tumors Using Human Monoclonal Antibody Against IGF-1R (R1507)
7. MacroChem Acquires Rights to Pexiganan, a Novel Topical Anti-Infective for Treatment of Diabetic Foot Infections, From Genaera
8. Rochester Medical Anti-Infection Foley Catheter Demonstrates Effectiveness in Randomized Trial
9. Researchers Identify Virus Possibly Responsible for Declining Honeybee Population Using 454 Sequencing Technology from Roche
10. Wyeths Torisel and Roche/Genentechs Avastin Will Challenge Pfizers Sutent to Become the Clinical Gold Standard for Treatment of Metastatic Renal Cell Carcinoma
11. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... July 31, 2014 TB Alliance, a ... better, faster and affordable treatments, announced the appointment ... President, External Affairs. Mr. Brock comes to TB ... Major Donor Relations for WWF International (formerly known ... Mr. Brock will guide the TB Alliance,s resource ...
(Date:7/31/2014)... -- Genomic Health, Inc. (Nasdaq: GHDX ) today announced ... on Thursday, August 7 at 4:30 p.m. Eastern Time to ... webcast will follow the release of the second quarter financial ... access the live conference call on August 7 at 4:30 ... the United States and ...
(Date:7/31/2014)... 31 2014  Northsight Capital, Inc. (OTCBB: NCAP) announced today ... Chairman and CEO of the company. Mr. Bluher has ... business development and investment banking. Mr. Bluher has over ... his career on Wall Street, Mr. Bluher was also ... Securities and Exchange Commission in Washington D.C. ...
Breaking Medicine Technology:TB Alliance Appoints Willo Brock Senior Vice President, External Affairs 2Genomic Health to Announce Second Quarter 2014 Financial Results and Host Conference Call on Thursday, August 7, 2014 2Genomic Health to Announce Second Quarter 2014 Financial Results and Host Conference Call on Thursday, August 7, 2014 3Genomic Health to Announce Second Quarter 2014 Financial Results and Host Conference Call on Thursday, August 7, 2014 4Northsight Capital, Inc. Names Wall Street Veteran John Bluher, Former EVP And General Counsel Of Knight Trading Group, Chairman And CEO. 2
... Alfacell Corporation,(Nasdaq: ACEL ) today announced that ... corporate secretary, will present an,overview of the company,s product ... at the UBS Global Life Sciences Conference at the ... Webcast of the presentation will be available on Alfacell,s,Web ...
... presented at the 43rd European Association for the Study of ... ... presented,today at the 43rd Annual Meeting of the European Association for ... the risk of ischemic cardiovascular disease in patients with type 2,diabetes. ...
Cached Medicine Technology:Alfacell Corporation to Present at UBS Global Life Sciences Conference 2ACTOS(R) (pioglitazone HCl) Demonstrates Reduced Risk of Ischemic Cardiovascular Disease in Patients with Type 2 Diabetes 2ACTOS(R) (pioglitazone HCl) Demonstrates Reduced Risk of Ischemic Cardiovascular Disease in Patients with Type 2 Diabetes 3
(Date:7/31/2014)... Alexandria, VA (PRWEB) July 31, 2014 ... Mesothelioma Applied Research Foundation, mesothelioma expert and executive ... APRN, stated that mesothelioma patients today have more promising ... In her talk, she mentioned several trials that have ... novel radiation treatments, while the focus of others is ...
(Date:7/31/2014)... Congress with bipartisan support would allow Medicare to test ... could improve the health of patients with chronic illness ... tests they need most. , The bill, introduced last ... grew out of a decade of work by health ... Policy and Innovation. It would allow Medicare Advantage plans ...
(Date:7/31/2014)... 31, 2014 Jacuzzi Luxury Bath, ... bathtub, has launched a new and improved website to ... , The Jacuzzi Luxury Bath website has been redesigned ... design and quality represented by the company’s products. The ... design and inspirational bathroom applications. “The site reflects our ...
(Date:7/31/2014)... at The Wistar Institute discovered that mice lacking ... age-related illnesses. The mice, which lack the TRAP-1 ... and spontaneous tumor formation when compared to normal ... the metabolic networks within cells. , In ... metabolism and has been shown to regulate energy ...
(Date:7/31/2014)... July 31, 2014 Global Markets ... provides an overview of the Brain Cancers therapeutic ... the therapeutic development for Brain Cancer, complete with ... drug target, mechanism of action (MoA), route of ... updates, and featured news and press releases. It ...
Breaking Medicine News(10 mins):Health News:‘More Promising Mesothelioma Clinical Trials than Ever Before,’ Says Expert 2Health News:‘More Promising Mesothelioma Clinical Trials than Ever Before,’ Says Expert 3Health News:Jacuzzi Luxury Bath Launches New and Improved Website 2Health News:'Rewired' mice show signs of longer lives with fewer age-related illnesses 2Health News:'Rewired' mice show signs of longer lives with fewer age-related illnesses 3Health News:Global Brain Cancer Market Size, Share, Analysis, Trends and Forecasts 2014 2Health News:Global Brain Cancer Market Size, Share, Analysis, Trends and Forecasts 2014 3Health News:Global Brain Cancer Market Size, Share, Analysis, Trends and Forecasts 2014 4
... October is National Physical Therapy,month and to ... Michigan residents to "Become a Physical Therapist or ... face uncertain economic times, the,physical therapy profession continues ... Director Aaron Bailey, PT, says there,is an urgent ...
... Oct. 30 Today URAC announced the,rollout ... technology,standards. The changes affect Health Web Site ... (Logo: http://www.newscom.com/cgi-bin/prnh/20030501/URACLOGO ), URAC, ... Privacy and Security standards to emphasize the ...
... International has named John T. Kelly, M.D., Ph.D. Chief Medical Officer. ... health and wellness of the users of Lifeclinic,s blood pressure monitors, ... ... MD (PRWEB) October 30, 2008 -- Lifeclinic International has ...
... CLEMSON Clemson University researchers developing imaging agents to ... received $180,000 from the Susan G. Komen Breast Cancer ... cancer deaths in American women. , The new method ... resonance imaging) that may help researchers look at different ...
... kick off American,Diabetes Month this November, the American ... Detroit, along with Eli,Lilly and Company,s national educational ... Diabetes Update, an educational program for people affected ... Saturday, November 1, at the Greater,Grace Temple, 23500 ...
... many hospitals have not,taken full advantage of opportunities ... see significant improvements in clinical,efficiencies, patient safety and ... Kermit Randa of Surgical Information Systems (SIS) and ... benefits realized through the,implementation of a best of ...
Cached Medicine News:Health News:The Physical Therapy Profession Remains in High Demand 2Health News:The Physical Therapy Profession Remains in High Demand 3Health News:URAC Rolls Out Revised Standards to Protect Personal Health Information and Boost Consumer Privacy on the Web 2Health News:Lifeclinic International Has Named John T. Kelly, M.D., Ph.D. Chief Medical Officer 2Health News:Susan G. Komen Breast Cancer Foundation awards grant for imaging-agent research 2Health News:American Diabetes Association and Eli Lilly and Company Unite to Educate and Empower African-Americans with Diabetes 2Health News:American Diabetes Association and Eli Lilly and Company Unite to Educate and Empower African-Americans with Diabetes 3Health News:Healthcare Providers Improve Financial, Clinical and Operational Efficiencies Through IT 2
... (TSH) is a 32 kDa glycoprotein secreted ... pituitary gland [1]. The structure of human ... pituitary and placental gonadotropins, consisting of an ... these hormones and a unique beta-subunit, which ...
... (T4) is the primary active hormone synthesized ... gland [1]. T4 is synthesized via a ... by the follicular cells, (ii) iodination of ... to formation of 3-monoiodotyrosine and 3,5-diiodotyrosine (MIT ...
... produced primarily by 5-monodeioination of thyroxine (T4) ... T3 production occurs at a rate which ... Release of T3 from the thyroid gland ... compared to 80-100 micrograms/day for T4. In ...
... protein-3 (IGFBP-3) is the main binding protein for ... component of the ~150 kDa ternary complex. This ... or IGF-II and ALS, allowing IGFBP-3, along with ... The molar concentration of IGFBP-3 in normal serum ...
Medicine Products: